LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM

• US 20090074852A1
• Filed: 04/20/2007
• Published: 03/19/2009
• Est. Priority Date: 04/20/2006
• Status: Abandoned Application

• Current Assignee: Silence Therapeutics Gmbh (Silence Therapeutics plc)
• Original Assignee: Silence Therapeutics AG
• Inventors: Kaufmann, Jorg, Santel, Ansgar, Keil, Oliver
• Application Number:
  US12/297,611
• Publication Number:
  US 20090074852A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The present invention is related to a lipid composition contained in and/or containing a carrier comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is optionally removable from the lipid composition under in vivo conditions, whereby the lipid composition containing carrier has an osmolarity of about 50 to 600 mosmole/kg, preferably about 250-350 mosmole/kg, and more preferably about 280 to 320 mosmole/kg, and/or whereby liposomes formed by the first lipid component and/or one or both of the helper lipid and the shielding compound in the carrier have a particle size of about 20 to 200 nm, preferably about 30 to 100 nm, and more preferably about 40 to 80 mm.

Claims

1-75. -75. (canceled)

76. A lipid composition contained in and/or containing a carrier comprising:

at least a first lipid component,

at least a first helper lipid, and

a shielding compound that may be removable from the lipid composition under in vivo conditions,

wherein the lipid composition containing carrier has an osmolarity of about 50 to 600 mosmole/kg, about 250-350 mosmole/kg, or about 280 to 320 mosmole/kg, and/or

wherein liposomes formed by the first lipid component and/or one or both of the helper lipid and the shielding compound in the carrier have a particle size of about 20 to 200 nm, about 30 to 100 nm, or about 40 to 80 nm.

77. The lipid composition according to claim 76, wherein the shielding compound is selected from PEG, HEG, polyhydroxyethyl starch (polyHES) or polypropylene.

78. The lipid composition according to claim 76, wherein the composition comprises a further constituent and/or a second helper lipid.

79. The lipid composition according to claim 76, wherein the shielding compound is a conjugate of PEG and ceramide.

80. The lipid composition according to claim 79, wherein the ceramide comprises at least one short carbon chain substituent of from 6 to 10 carbon atoms.

81. The lipid composition according to claim 76, wherein the ceramide is the first helper lipid.

82. The lipid composition according claim 78, wherein the ceramide is the second helper lipid.

83. The lipid composition according to claim 76, wherein the shielding compound comprises a pH-sensitive linker or a pH-sensitive moiety.

84. The lipid composition according to claim 83, wherein the linker or moiety is an anionic linker or an anionic moiety.

85. The lipid composition according to claim 76, wherein the first lipid component is a compound according to formula (I),

wherein R₁ and R₂ are each and independently alkyl;

n is any integer between 1 and 4;

R₃ is an acyl selected from the group consisting of lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II),

wherein m is any integer from 1 to 3, wherein the NH₃⁺ is optionally absent, and

Y⁻

is a pharmaceutically acceptable anion.

86. The lipid composition according to claim 85, wherein R₁ and R₂ are each and independently selected from the group consisting of lauryl, myristyl, palmityl and oleyl.

87. The lipid composition according to claim 85, wherein R₁ is lauryl and R₂ is myristyl;

or R₁ is palmityl and R₂ is oleyl.

88. The lipid composition according to claim 85, wherein the compound is a cationic lipid, in association with an anion Y⁻

.

89. The lipid composition according to claim 85, wherein Y⁻

is selected from the group consisting of halogenids, acetate and trifluoroacetate.

90. The lipid composition according to claim 85, wherein the compound is selected from:

β

-arginyl-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide trihydrochloride

β

-arginyl-2,3-diamino propionic acid-N-lauryl-N-myristyl-amide trihydrochloride

ε

-arginyl-lysine-N-lauryl-N-myristyl-amide trihydrochloride

91. The composition according to claim 76, wherein the composition contains one or several basic amino acids or weak bases.

92. The composition according to claim 91, wherein the amino acid is selected from the group consisting of histidine, lysine, and arginine.

93. The composition according to claim 91, wherein the weak base is selected from TRIS or ethanolamine.

94. The lipid composition according to claim 76, wherein the lipid composition further comprises a nucleic acid.

95. The lipid composition according to claim 94, wherein a shielding compound is attached to the nucleic acid.

96. The lipid composition according to claim 76, wherein the composition comprises a nucleic acid and the nucleic acid forms together with the liposome a lipoplex.

97. The lipid composition according to claim 76, wherein the concentration of the lipids in the carrier is about from 0.01 to 100 mg/ml, about from 0.01 to 40 mg/ml or about from 0.01 to 25 mg/ml, each based on the overall amount of lipid provided by the lipoplex.

98. The lipid composition according to claim 96, wherein the nucleic acid is an siRNA and the concentration of the siRNA in the lipid composition is about 0.2 to 0.4 mg/ml, 0.28 mg/ml, and the total lipid concentration is about 1.5 to 2.7 mg/ml, 2.17 mg/ml.

99. A pharmaceutical composition comprising a lipid composition according to claim 76 and a pharmaceutically acceptable carrier.

100. The composition according to claim 99, further comprising a pharmaceutically active compound.

101. The composition according to claim 76, wherein the helper lipid component is selected from 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine or 1,2-dioleyl-sn-glycero-3-phosphoethanolamine.

105. A method of treating an angiogenesis-dependent disease comprising the administration of a composition according to claim 94 to an individual in need of treatment.

106. The method according to claim 105, wherein the disease is cancer or a solid tumor.

107. The method according to claim 105, wherein the disease is selected from neoplastic diseases, bone cancer, breast cancer, prostate cancer, cancer of the digestive system, colorectal cancer, liver cancer, lung cancer, kidney cancer, urogenital cancer, pancreatic cancer, pituitary cancer, testicular cancer, orbital cancer, head and neck cancer, cancer of the central nervous system or cancer of the respiratory system.

108. The method according to claim 105, further comprising an additional therapy selected from chemotherapy, cryotherapy, hyperthermia, antibody therapy or radiation therapy.

109. A method for transferring a pharmaceutically active compound and/or a constituent into a cell or across a membrane, comprising the following steps:

providing the cell or the membrane;

providing a composition according to claim 76 and a pharmaceutically active compound and/or a constituent; and

contacting the cell or the membrane with the composition.

110. The method according to claim 109, wherein the method further comprises detecting the pharmaceutically active compound and/or the further constituent in the cell and/or beyond the membrane.

102. A lipoplex comprising:

a) a positively charged liposome consisting of;

aa) about 50 mol % β

3-arginyl-2,3-diaminopropionic acid-N-palmityl-N-oleyl-amide trihydrochloride, (β

-(L-arginyl)-2,3-L-diaminopropionic acid-N-palmityl-N-oleyl-amide tri-hydrochloride);

ab) about 48 to 49 mol % 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhyPE); and

ac) about 1 to 2 mol % 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylen-glycole, N—

(Carbonyl-methoxypolyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt; and

b) a functional nucleic acid, a siRNA.

103. The lipoplex according to claim 102, wherein the zeta-potential of the lipoplex is about 40 to 55 mV or about 45 to 50 mV.

104. The lipoplex according to claim 102, wherein the lipoplex has a size of about 80 to 200 nr, of about 100 to 140 nm, or about 110 nm to 130 nm, as determined by QELS.